BioCentury
ARTICLE | Clinical News

Ceftolozane/tazobactam: Phase III started

July 22, 2013 7:00 AM UTC

Cubist began the open-label, U.S. and Australian Phase III VECTOR trial comparing 3,000 mg IV ceftolozane/tazobactam every 8 hours vs. 4,500 mg piperacillin/tazobactam every 6 hours in about 300 patients. The product is in Phase III testing to treat complicated urinary tract infection (cUTI) and complicated intra-abdominal infections (cIAIs) caused by Gram-negative bacteria and multi-drug resistant Pseudomonas aeruginosa, with data slated for next quarter. The product has Fast Track and Qualified Infectious Disease Product (QIDP) designation in the U.S. to treat VABP, cUTI, cIAIs and hospital-acquired bacterial pneumonia (HABP) (see BioCentury, Dec. 17, 2012 & March 11, 2013). ...